The South Korea Antirheumatic Drugs market is forecast to grow at a CAGR of 3.8%, reaching USD 6.9 billion in 2031 from USD 5.7 billion in 2026.
The country's demographic transition toward a "super-aged" society drives demand for anti-rheumatic drugs in South Korea. The proportion of the population aged 65 and above is increasing significantly, directly correlating with a higher incidence of age-related autoimmune and degenerative joint disorders. Unlike short-term demand spikes, this growth is a permanent shift in the epidemiological profile of the nation, requiring long-term, high-cost maintenance therapies. The industry is heavily dependent on the National Health Insurance (NHI) reimbursement framework managed by the Health Insurance Review and Assessment Service (HIRA), which determines the commercial viability of new therapeutics through pharmacoeconomic evaluations and risk-sharing models.
Technology and process evolution within the South Korean market are increasingly centered on the development of biosimilars and cell therapies. South Korea has established itself as a global hub for biosimilar manufacturing, with local firms leveraging advanced bioprocessing platforms to produce cost-effective alternatives to originator biologics. Regulatory influence from the Ministry of Food and Drug Safety (MFDS) has recently intensified, with new mandates for pharmaceutical data protection and safety data sheet (SDS) reforms. The strategic importance of the anti-rheumatic sector is further underscored by the government's Second Comprehensive National Health Insurance Plan (2024–2028), which incentivizes the development of innovative drugs for severe, irreversible diseases.
Aging Demographics and Chronic Disease Prevalence: The rapid rise in the geriatric population is structurally increasing the patient pool for osteoarthritis and rheumatoid arthritis, necessitating a higher volume of long-term prescription therapies.
Expansion of Biosimilar Access: Government policies promoting biosimilars to reduce the NHI fiscal burden are lowering treatment costs, thereby increasing the number of patients eligible for high-efficacy biologic treatments.
Refinement of Risk-Sharing Agreements (RSA): The expansion of RSA eligibility to include drugs for severe diseases causing irreversible deterioration (revised in August 2024) is facilitating the market entry of expensive, innovative anti-rheumatic biologics.
Rise in Lifestyle-Related Metabolic Disorders: Increasing incidences of obesity and sedentary lifestyles are accelerating the onset of metabolic-related joint conditions like gout and obesity-linked osteoarthritis.
Stringent Reimbursement Criteria: The discrepancy between international clinical guidelines and Korean NHI reimbursement standards (often requiring higher active joint counts) remains a significant barrier to the adoption of advanced biologics.
Safety and Regulatory Compliance Costs: Recent reforms in Safety Data Sheet (SDS) regulations (Notification No. 2025-50) and chemical hazardousness reclassifications impose new administrative and testing burdens on pharmaceutical manufacturers.
Opportunities in Personalized Medicine: The integration of biomarkers and genomic screening allows for precision therapy selection, presenting an opportunity for premium-priced targeted inhibitors in clinical practice.
Emerging Demand for Oral Formulations: Increasing patient preference for oral JAK inhibitors over traditional injectable biologics offers a strategic opportunity for firms to capture market share through improved treatment adherence.
The supply chain for anti-rheumatic drugs in South Korea is defined by high production concentration in biopharmaceutical clusters like Incheon, particularly for biosimilars. Production is characterized by high technological intensity rather than energy intensity, requiring strictly controlled GMP environments and cold-chain logistics for biologic products. The supply chain for traditional small-molecule NSAIDs is more fragmented, with a significant reliance on imported Active Pharmaceutical Ingredients (APIs) that are subject to global tariff and cost fluctuations.
Recent regulatory changes have introduced a dual punishment system for illegal rebates and mandatory expenditure reporting for Contract Sales Organizations (CSOs) as of October 2024. This ensures a more transparent but administratively complex promotional environment. Regional risk exposure is primarily linked to the centralized nature of specialty pharmacies and hospital hubs, which necessitates robust distribution networks to reach peripheral regions. Integrated manufacturing strategies, such as Samsung Biologics’ utilization of dedicated plants for global partnerships, are becoming the standard to ensure stable domestic and export supplies.
Jurisdiction | Key Regulation / Agency | Market Impact Analysis |
South Korea | Ministry of Food and Drug Safety (MFDS) | Implements the Pharmaceutical Data Protection System (2025), replacing the post-market re-examination program with fixed exclusivity periods for new drugs. |
South Korea | Health Insurance Review and Assessment Service (HIRA) | Revised evaluation criteria (August 2024) to expand RSA eligibility for innovative drugs treating severe, irreversible diseases. |
South Korea | Ministry of Employment and Labor (MoEL) | Notification No. 2025-50 overhauls Safety Data Sheet (SDS) formats, requiring reclassification of chemicals into hazard categories by mid-2026. |
Global | ICH Guidelines | South Korea’s full adoption ensures global consistency in clinical trial conduct and drug safety monitoring for anti-rheumatic biologics. |
November 2024: Celltrion – Received MFDS approval for denosumab biosimilars (Stavoklone and Oseni Belt), referencing Prolia and Xgeva. This marks a strategic expansion into bone-health-related anti-rheumatic therapies.
October 2024: Dong-A ST – Obtained U.S. FDA approval for Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara for psoriatic arthritis. This development highlights the global manufacturing readiness and R&D capability of South Korean domestic firms.
The osteoarthritis segment is driven by the structural intersection of an aging population and rising obesity rates in South Korea. Market revenue is increasingly concentrated in viscosupplementation agents and injectables, with hyaluronic acid injections representing a major growth sub-segment. Demand in this segment is less reliant on high-cost biologics compared to RA, focusing instead on pain management and functional preservation through NSAIDs and intra-articular therapies. The operational advantage for firms in this segment lies in the high volume of recurring treatments required for chronic degenerative conditions, supporting steady revenue through retail and hospital pharmacies.
DMARDs, particularly biologics and biosimilars, represent the highest-value segment of the South Korean market. The segment is structurally evolving from non-targeted therapies to biosimilars of TNF inhibitors and IL-6 inhibitors. Demand is heavily influenced by HIRA reimbursement policies, which are gradually expanding to include a broader range of biosimilars to offset the high costs of originator biologics. Furthermore, the introduction of targeted synthetic DMARDs (tsDMARDs) is changing the competitive landscape by providing oral alternatives that do not require the cold-chain logistics and administration infrastructure of traditional biologics.
The prescription sales channel dominates the anti-rheumatic drug market in South Korea, accounting for a significant majority of total revenue. This is due to the chronic and complex nature of rheumatic diseases, which require professional diagnosis and ongoing physician monitoring for dose adjustments and safety surveillance. The operational advantage of this channel is sustained by the NHI system, which covers a large portion of prescription costs for patients meeting eligibility criteria, thereby ensuring high patient adherence to prescribed biologic regimens compared to self-medicated OTC options.
AbbVie Inc.
Amgen Inc.
Johnson & Johnson
Pfizer Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Eli Lilly and Company
Novartis AG
Bristol-Myers Squibb (Celgene Corporation)
Celltrion Inc.
Samsung Bioepis
Dong-A ST
Celltrion maintains a unique market position in South Korea as a pioneer of the "Biosimilar First" strategy, having successfully launched several world-first biosimilars for autoimmune diseases. The company’s strategy centers on aggressive domestic market penetration followed by global export, utilizing its large-scale manufacturing capacity in Incheon to achieve economies of scale. Its competitive advantage is built on a robust R&D pipeline that includes biobetters and subcutaneous formulations, such as Remsima SC, which allows for self-administration and differentiates its portfolio from traditional IV-only biologics.
Samsung Bioepis operates through an integrated R&D model that leverages the massive manufacturing infrastructure of its parent organization, Samsung Biologics. The company’s competitive strategy is built on rapid clinical development and global commercial partnerships with firms like Biogen and Organon to maximize market reach. Its technology differentiation lies in advanced bioprocessing and analytical capabilities that ensure high similarity to reference products, allowing it to capture significant market share in the RA and psoriatic arthritis segments in South Korea.
Dong-A ST is a leading domestic pharmaceutical firm that has recently transitioned from traditional generics to advanced biopharmaceutical development. The company's unique position is highlighted by its recent U.S. FDA approval for a biosimilar referencing Stelara, proving its capability to meet stringent international standards. Its geographic strength is rooted in its extensive domestic distribution network and long-standing relationships with Korean healthcare providers, which it leverages to promote its diverse portfolio of anti-rheumatic and metabolic disease treatments.
Aging demographics and expanded biosimilar reimbursement drive structural growth in South Korea's anti-rheumatic market. While stringent HIRA joint-count criteria and new MFDS safety reporting burdens persist, advancements in oral targeted inhibitors and innovative risk-sharing models offer significant long-term expansion opportunities.
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 5.7 billion |
| Total Market Size in 2031 | USD 6.9 billion |
| Forecast Unit | Billion |
| Growth Rate | 3.8% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Type of Disease, Drug Class, Sales Channel |
| Companies |
|